Skip to main content
. 2020 Feb 17;19:1533033819886896. doi: 10.1177/1533033819886896

Figure 4.

Figure 4.

Histological sections of tumors from each treatment group to show the histological modification. Magnified zones show the different levels of necrosis: the diffuse necrosis in combined and monotherapy antiangiogenic drug groups (more in Ziv-aflibercet than Sorafenib). The placebo group presented centralized necrosis surrounded by viable tumor.